We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Arena (ARNA) This Earnings Season?
Read MoreHide Full Article
Arena Pharmaceuticals, Inc. is expected to report first-quarter 2018 earnings in the second week of this month.
Shares of the company have rallied 17.2% against the industry’s 10.9% decrease so far this year.
Arena’s earnings performance has been a mixed bag over the trailing four quarters. While the company surpassed expectations in two of the last four quarters, it missed the same on another couple of occasions with an average beat of 5.10%.
Last reported quarter, the company outpaced the Zacks Consensus Estimate with a positive earnings surprise of 44.62%.
Let’s see, how things are shaping up prior to this announcement.
Factors at Play
The only approved product in Arena’s portfolio is obesity treatment drug, Belviq, which delivered an unimpressive performance last year. We note that ramping up sales in U.S. anti-obesity market is challenging due to several factors including the tendency of health care providers to treat obesity symptoms instead of the disease itself, lesser focus on certain patient types for the therapy and historically, low third-party insurance coverage. We expect this trend to continue in first-quarter release as well.
However, Arena’s Japanese pharma partner Eisai is working to utilize certain cost-efficient strategies to market Belviq in new, untapped areas. To that end, specific parts of the country with high obesity rates and insurance coverage are mainly being earmarked to target opportunities for the same.
Arena has a few pipeline candidates and updates on the same are expected on first-quarter conference call. In the second half of 2017, the company presented positive results from a phase II study, evaluating its key pipeline candidate, ralinepag, for the treatment of pulmonary arterial hypertension (PAH). The company expects to start the phase III analysis on the candidate during the second half of 2018 for the given indication.
Other candidates include etrasimod and APD371, both being evaluated in phase II trials for the respective ulcerative colitis and pain management associated with Crohn’s disease.
Notably, this March, Arena announced that etrasimod met the primary endpoint in the phase II study. The candidate achieved statistically significant improvements in primary as well as secondary endpoints. The company believes that etrasimod has potential to be developed for additional indications beyond an inflammatory bowel disease.
What Our Model Indicates
Our proven model does not conclusively show that Arena is likely to beat on earnings this last completed quarter. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Zacks ESP: Arena has an Earnings ESP of 0.00% because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 70 cents.You can uncover the best stocks to buy or sell before they’re reported with ourEarnings ESP Filter.
Zacks Rank: Arena has a Zacks Rank #3, which increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult.
We caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Arena Pharmaceuticals, Inc. Price and EPS Surprise
Vanda Pharmaceuticals Inc. (VNDA - Free Report) has an Earnings ESP of +25.00% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 2.
Adverum Biotechnologies, Inc. (ADVM - Free Report) has an Earnings ESP of +6.90% and is a Zacks #3 Ranked player. The company is expected to release first-quarter results on May 8.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
What's in the Cards for Arena (ARNA) This Earnings Season?
Arena Pharmaceuticals, Inc. is expected to report first-quarter 2018 earnings in the second week of this month.
Shares of the company have rallied 17.2% against the industry’s 10.9% decrease so far this year.
Arena’s earnings performance has been a mixed bag over the trailing four quarters. While the company surpassed expectations in two of the last four quarters, it missed the same on another couple of occasions with an average beat of 5.10%.
Last reported quarter, the company outpaced the Zacks Consensus Estimate with a positive earnings surprise of 44.62%.
Let’s see, how things are shaping up prior to this announcement.
Factors at Play
The only approved product in Arena’s portfolio is obesity treatment drug, Belviq, which delivered an unimpressive performance last year. We note that ramping up sales in U.S. anti-obesity market is challenging due to several factors including the tendency of health care providers to treat obesity symptoms instead of the disease itself, lesser focus on certain patient types for the therapy and historically, low third-party insurance coverage. We expect this trend to continue in first-quarter release as well.
However, Arena’s Japanese pharma partner Eisai is working to utilize certain cost-efficient strategies to market Belviq in new, untapped areas. To that end, specific parts of the country with high obesity rates and insurance coverage are mainly being earmarked to target opportunities for the same.
Arena has a few pipeline candidates and updates on the same are expected on first-quarter conference call. In the second half of 2017, the company presented positive results from a phase II study, evaluating its key pipeline candidate, ralinepag, for the treatment of pulmonary arterial hypertension (PAH). The company expects to start the phase III analysis on the candidate during the second half of 2018 for the given indication.
Other candidates include etrasimod and APD371, both being evaluated in phase II trials for the respective ulcerative colitis and pain management associated with Crohn’s disease.
Notably, this March, Arena announced that etrasimod met the primary endpoint in the phase II study. The candidate achieved statistically significant improvements in primary as well as secondary endpoints. The company believes that etrasimod has potential to be developed for additional indications beyond an inflammatory bowel disease.
What Our Model Indicates
Our proven model does not conclusively show that Arena is likely to beat on earnings this last completed quarter. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Zacks ESP: Arena has an Earnings ESP of 0.00% because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 70 cents.You can uncover the best stocks to buy or sell before they’re reported with ourEarnings ESP Filter.
Zacks Rank: Arena has a Zacks Rank #3, which increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult.
We caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Arena Pharmaceuticals, Inc. Price and EPS Surprise
Arena Pharmaceuticals, Inc. Price and EPS Surprise | Arena Pharmaceuticals, Inc. Quote
Stocks to Consider
A few health care stocks with the right combination of elements to beat estimates this time around are as follows:
Emergent Biosolutions Inc. (EBS - Free Report) has an Earnings ESP of +61.80% and a Zacks Rank of 3. The company is scheduled to release first-quarter results on May 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vanda Pharmaceuticals Inc. (VNDA - Free Report) has an Earnings ESP of +25.00% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 2.
Adverum Biotechnologies, Inc. (ADVM - Free Report) has an Earnings ESP of +6.90% and is a Zacks #3 Ranked player. The company is expected to release first-quarter results on May 8.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>